Cartesian Technologies

Cartesian Therapeutics is a clinical-stage biotechnology company pioneering mRNA-engineered cell therapies for the treatment of autoimmune diseases. The company's proprietary RNA Armory platform enables the precision engineering of cells to produce various therapeutic proteins, offering a potentially safer and more scalable alternative to conventional DNA-based cell therapies. Its lead candidate, Descartes-08, is a first-in-class mRNA CAR-T therapy currently in Phase 2 clinical trials for generalized myasthenia gravis and systemic lupus erythematosus. By utilizing mRNA rather than viral vectors, Cartesian aims to avoid the risks of genomic integration and enable outpatient administration of cell therapies. The company became publicly traded in late 2023 following a merger with Selecta Biosciences.